Table 5.
Characteristics and efficacy results from clinical trials assessing neoadjuvant immunotherapy
| Clinical trail | Sample size | Stage | Stage III (%) | Drugs | Cycles | Surgical resection rate (%) | MPR (%) | pCR(%) |
|---|---|---|---|---|---|---|---|---|
| Checkmate 159 | 21 | I–IIIA | 33% | Nivolumab | 2 | 95.2% (20/21) | 45% (9/20) | 15% (3/20) |
| LCMC3 | 181 | IB–IIIB | 49% | Atezolizumab | 2 | 88% (159/181) | 20% (29/143)a | 6% (8/143)a |
| NEOSTAR | 44 | I–IIIA | 22% | Nivolumab/Ipilimumab | 3 | 82.9% (34/41) |
N 22% (5/23) NI 38% (8/21) |
N 9% (2/23) NI 29% (6/21) |
| Sintilimab (ChiCTR-OIC-17013726) | 40 | IB–IIIA | 45.5% | Sintilimab | 2 | 92.5% (37/40) | 40.5% (15/37) | 16.2% (6/37) |
| NADIM | 41 | IIIA | 100% | Nivolumab + CBDCA-pacilitaxel | 3 | 89.1% (41/46) | 83% (34/41) | 63% (26/41) |
| Checkmate 816 | 358 | IB–IIIA | 63.7% | Nivolumab + platinum-doublet chemotherapy | 3 | 83%(149/179) | 46.8%(66/14) | 30.5%(43/141) |
| NCT02716038 | 30 | IB–IIIA | 77% | Atezolizumab + CBDCA-nab pacilitaxel | 4 | 97%(29/30) | 57% (17/30) | 33% (9/30) |
| SAKK16/14 | 68 | IIIA | 100% | CDDP-docetaxel followed by durvalumab | 3 | 82% (55/67) | 62% (34/55) | 18% (10/55) |
aThese percentages exclude patients with EGFR/ALK + . CBDCA carboplatin, CDDP cisplatin, MPR major pathological response (≤ 10% viable tumor cells), pCR pathological complete response (0% viable tumor cells)